NKTRNektar Therapeutics
$58.57
$1.79
(3.15%)
EarningsAug 6
Mkt Cap$1.92B
Vol179,154.00
Fundamentals
Mkt Cap
$1.92B
Volume
-
52W High
$109.00
52W Low
$7.99
PE Ratio
-6.74
Avg. Volume
864,814.68
EPS (Annual)
-$9.73
Rev/Employee
$876,698.41
Earnings
Aug 06
What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock
What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock...
Yahoo! Finance: News
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, June 3, 2026 SAN FRANCISCO, June 3, 2026 /PRNewswire/ --Nektar Therapeutics (NASDAQ: NKTR) today announced...
PR Newswire
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York PR Newswire SAN FRANCISCO, May 27, 2026 SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar...
PR Newswire
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
Key PointsProsight Management increased its Nektar Therapeutics holding by 180,367 shares last quarter, an estimated $10.27 million buy based on average prices during the quarter...
Nasdaq News: Markets
Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus
NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.
Zacks
Nektar Therapeutics Reports First Quarter 2026 Financial Results
Nektar Therapeutics Reports First Quarter 2026 Financial Results Nektar Therapeutics Reports First Quarter 2026 Financial Results PR Newswire SAN FRANCISCO, May 7, 2026 SAN FRANCISCO, May 7, 2026...
PR Newswire
NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds...
PR Newswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May...
PR Newswire
NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit PR Newswire NEW YORK, May 4, 2026 NEW YORK, May 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a...
PR Newswire
Deadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz reminds investors of the upcoming May 5, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors...
Business Wire
<
1
2
...
>
Advertisement|Remove ads.
Latest NKTR News
ViewWhat Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock
Yahoo! Finance: News
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
PR Newswire
Advertisement|Remove ads.